ARTICLE | Management Tracks
Plus: Lee Patterson becomes CEO of Metrion, and updates from Rondo, AffyImmune and Aspargo
By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst
November 26, 2024 12:12 AM UTC
Paragon Therapeutics Inc. named Susanna High CEO. High was COO of Dyne Therapeutics Inc. (NASDAQ:DYN), before which she worked at Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) for almost a decade. Backed by Fairmount Funds, Paragon incubates companies focused on developing biologics; its spinout Crescent Biopharma Inc. announced last month it is going public via a reverse merger with GlycoMimetics Inc. (NASDAQ:GLYC).
Lee Patterson became CEO of Metrion Biosciences Ltd., a preclinical contract research organization. Patterson, who succeeds Andrew Southan, was CEO of Charnwood Discovery Ltd., which was acquired last month by Concept Life Sciences…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654317/susanna-high-named-ceo-of-paragon